{"name":"Intergroupe Francophone du Myelome","slug":"intergroupe-francophone-du-myelome","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bendamustine, Velcade and Dexamethasone","genericName":"Bendamustine, Velcade and Dexamethasone","slug":"bendamustine-velcade-and-dexamethasone","indication":"Multiple myeloma","status":"phase_2"},{"name":"Velcade-Dexamethasone","genericName":"Velcade-Dexamethasone","slug":"velcade-dexamethasone","indication":"Multiple myeloma","status":"phase_3"}]}],"pipeline":[{"name":"Bendamustine, Velcade and Dexamethasone","genericName":"Bendamustine, Velcade and Dexamethasone","slug":"bendamustine-velcade-and-dexamethasone","phase":"phase_2","mechanism":"Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2.","indications":["Multiple myeloma"],"catalyst":""},{"name":"Velcade-Dexamethasone","genericName":"Velcade-Dexamethasone","slug":"velcade-dexamethasone","phase":"phase_3","mechanism":"Velcade-Dexamethasone is a combination of a proteasome inhibitor and a corticosteroid used to treat multiple myeloma.","indications":["Multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1PUVdxNlhac2RIZTdaYmE0R2xuMWNjZ0JWRlF3dk9WWVJGUlk1UUs2ODRKTmNIUXZlQlYxdmN1Zkk2ZHJEU1R5dXJ1UFA3V2J3NE1uYXpGWWFBQQ?oc=5","date":"2025-06-03","type":"pipeline","source":"NEJM","summary":"Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma - NEJM","headline":"Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5wUWw0b3hDTldWbGdaSWFnb0VNcmF5S2hzM3FCRW1OMndKanl6cVNvWFNQdEt0VUR4cjBNbVg2ckdKYm1FeEFacDBLRlVGcG5YaEhTTS16ZnpSMGYyLXUzcnNhaw?oc=5","date":"2024-05-15","type":"trial","source":"Wiley Online Library","summary":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR","headline":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with rela","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxObW9HelNJM3FLMHdOa1dpeTdzT3hFWDV3cTIyc1ByLWRKd0xpLV9KTDhCU0hPRTIwN004WTBMTmU3N0JZdGtNY2VpTmNBRmllcTJPRW5kdUdQNDNJa1o0T05fQmNNUzk3VEtMRnFqbmZXTlpBbGpIRVYyVFZPMGFMVkNabTAzazA?oc=5","date":"2021-09-30","type":"regulatory","source":"Via Medica Journals","summary":"Treatment options for relapsed/refractory multiple myeloma in Poland within the reach of the Ministry of Health drug program in relation to European Society for Medical Oncology recommendations | Char","headline":"Treatment options for relapsed/refractory multiple myeloma in Poland within the reach of the Ministry of Health drug pro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOWTlwU1ZsLUdROTFLdG10cmxSR3NLTmlHdjBfSEN3TlFhd2s2TnotUm5oNHNpSXBrU194LTZDS3ZTaGx2TkZzQmpmRk9HN1F1UFNMUV9pcjJmdmJxNmR2WHp5dklsdW9TQWtMbEZQN2wtRDkxa1BaVXMyWVE4QVNYZkF5QkxfMFBYemRGYkxSLUJnVHZWa3RFMnB3?oc=5","date":"2020-01-31","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma - The American Journal of Managed Care® (AJMC®)","headline":"Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma - The American Journal of Managed Care® (AJMC®)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOa1JCUk1KaDRaN2F2dzVCVXJlM2NMRXUtTERoUDlTTkdER25KTTFTeW8xOGUwaWVWbGtMbkhEX1ZIWS1uenJSR3J2ZzV2QU84X04wenc1bE9XdkM0dHlkRFNUVVlKQXJncnJzLUNFSkFjRWVZdk1tOHJkVWIwSk9pV0JkTlhNcC1kbmpwR1M5Q1NsMUFjc2VPNHVMZF9LRzl6c1U4N3lMZXVSSl9xZlBuWWpya0tXQVBKRzlpWA?oc=5","date":"2016-06-03","type":"pipeline","source":"Roswell Park Comprehensive Cancer Center","summary":"Lenalidomide Maintenance Therapy Improves Overall Survival for Patients with Multiple Myeloma - Roswell Park Comprehensive Cancer Center","headline":"Lenalidomide Maintenance Therapy Improves Overall Survival for Patients with Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1lQzd6SkR6dlVyQVg2Q3E0NkRlT01yYlJ0OGxDYnFUQzhGOEp6S1JBTDVGVnhXUGN2TW80QzZ2VTJ0OFJTdXhTZnkweGNxaUdMSEZXR255NA?oc=5","date":"2016-05-19","type":"pipeline","source":"ASCO Publications","summary":"Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy - ASCO Publications","headline":"Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Imm","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}